Efficacy and Safety of ATL-962 in Obese Diabetics

PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

October 31, 2005

Conditions
Non-Insulin-Dependent Diabetes MellitusObesity
Interventions
DRUG

ATL-962

DRUG

Orlistat

Trial Locations (37)

20520

Turku University Hospital, Turku

27510

Lääkärikeskus Minerva, Eura

40100

Suomen Terveystalo, Jyväskylä

90100

Oulun Diakonissalaitos, Oulu

Unknown

Aalborg Sygehus Nord, Aalborg

Odense University Hospital, Odense

Oy Foodfiles Limited, Kuopio

University of Oulu, Oulu

Allevon, Den Bosch Ziekenhuis

Allevon, DN de Bilt

Zeikenhuisgroep Twente, Hengelo

Nederlandse Obesitas Klinik, Hilversum

Sint Franciscus Gasthuis, Rotterdam

Sahlgrenska University Hospital, Gothenburg

Linkoping University Hospital, Linköping

Karolinsaka University Hospital, Stockholm

Norrlands Universitetssjukhus, Umeå

Samariterhemmets Sjukhus, Uppsala

Aberdeen Royal Infirmary, Aberdeen

Royal United Hospital, Bath

Clinical Research Centre Edgbaston, Birmingham

Walsgrave Hospital, Coventry

Glasgow Royal Infirmary, Glasgow

Clinical Research Centre, Crosby, Liverpool

Liverpool University Hospital, Liverpool

Hammersmith Hospital, London

Luton & Dunstable Hospital, Luton

Clinical Research Centre, Manchester

James Cook University Hospital, Middlesbrough

Royal Shrewsbury Hospital, Shrewsbury

Clinical Research Centre, Wigan

DK-8000

Aarhus University Hospital, Aarhus

DK-2400

Bispebjerg Hospital, Copenhagen

DK-2900

Gentofte Hospital, Hellerup

DK-2650

Hvidovre Hospital, Hvidovre

00100

Obesity Research Unit, Helsinki

E1 2AA

Queen Mary's School of Medicine & Dentistry, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alizyme

INDUSTRY

NCT00156897 - Efficacy and Safety of ATL-962 in Obese Diabetics | Biotech Hunter | Biotech Hunter